Immunotherapy of hepatocellular carcinoma

Journal of Hepatology

Volumn 45, Issue 6, 2006, Pages 868-878

  Greten, Tim F ^a   Manns, Michael P ^a   Korangy, Firouzeh ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; BETA INTERFERON; CANCER ANTIBODY; CANCER VACCINE; CD137 ANTIBODY; CD3 ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; DEFEROXAMINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; INTERLEUKIN 12; INTERLEUKIN 2; IODINATED POPPYSEED OIL; LYMPHOCYTE ANTIBODY; MELATONIN; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 131I HEPAMA 1; TAMOXIFEN; THYMOSIN ALPHA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADENOVIRUS VECTOR; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ANGIOGENESIS; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CELL STRAIN HEPG2; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EXPRESSION VECTOR; GENETIC TRANSDUCTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VIVO STUDY; INTERMETHOD COMPARISON; KIDNEY CANCER; LIVER CELL CARCINOMA; LOW DRUG DOSE; LYMPHOKINE ACTIVATED KILLER CELL; MORRIS HEPATOMA; NONHUMAN; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LIVER NEOPLASMS; TREATMENT OUTCOME;

EID: 33750487815     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.09.004     Document Type: Review

References (153)

1. Bruix J., Boix L., Sala M., and Llovet J.M. Focus on hepatocellular carcinoma. Cancer Cell 5 (2004) 215-219
2. Greten T.F., Papendorf F., Bleck J.S., Kirchhoff T., Wohlberedt T., Kubicka S., et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 92 (2005) 1862-1868
3. Bruix J., Sala M., and Llovet J.M. Chemoembolization for hepatocellular carcinoma. Gastroenterology 127 (2004) S179-S188
4. Greten T.F., Blum H.E., Manns M.P., and Geissler M. Therapie des hepatozellulären Karzinoms. Z Gastroenterol 44 (2006) 43-49
5. Beaugrand M., N'Kontchou G., Seror O., Ganne N., and Trinchet J.C. Local/regional and systemic treatments of hepatocellular carcinoma. Semin Liver Dis 25 (2005) 201-211
6. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol 35 (2001) 421-430
7. Sherman M., and Klein A. AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings. Hepatology 40 (2004) 1465-1473
8. Wada Y., Nakashima O., Kutami R., Yamamoto O., and Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27 (1998) 407-414
9. Butterfield L.H. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 127 (2004) S232-S241
10. Dudley M.E., and Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3 (2003) 666-675
11. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., and Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188 (1998) 2357-2368
12. Gerloni M., and Zanetti M. CD4 T cells in tumor immunity. Springer Semin Immunopathol 27 (2005) 37-48
13. Van Der Bruggen P., Zhang Y., Chaux P., Stroobant V., Panichelli C., Schultz E.S., et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188 (2002) 51-64
14. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2 (2002) 514-520
15. Butterfield L.H., Koh A., Meng W., Vollmer C.M., Ribas A., Dissette V., et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 59 (1999) 3134-3142
16. Butterfield L.H., Meng W.S., Koh A., Vollmer C.M., Ribas A., Dissette V.B., et al. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 166 (2001) 5300-5308
17. Meng W.S., Butterfield L.H., Ribas A., Heller J.B., Dissette V.B., Glaspy J.A., et al. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. Mol Immunol 37 (2000) 943-950
18. Mizukoshi E., Nakamoto Y., Tsuji H., Yamashita T., and Kaneko S. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer (2005)
19. Alisa A., Ives A., Pathan A.A., Navarrete C.V., Williams R., Bertoletti A., et al. Analysis of CD4+ T-cell responses to a novel {alpha}-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin Cancer Res 11 (2005) 6686-6694
20. Fujii T., Nomoto S., Koshikawa K., Yatabe Y., Teshigawara O., Mori T., et al. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology (2006)
21. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., and Chen Y.T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188 (2002) 22-32
22. Chen Y.T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94 (1997) 1914-1918
23. Korangy F., Ormandy L.A., Bleck J.S., Klempnauer J., Wilkens L., Manns M.P., et al. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10 (2004) 4332-4341
24. Peng J.R., Chen H.S., Mou D.C., Cao J., Cong X., Qin L.L., et al. Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett 219 (2005) 223-232
25. Bricard G., Bouzourene H., Martinet O., Rimoldi D., Halkic N., Gillet M., et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol 174 (2005) 1709-1716
26. Chen H.S., Qin L.L., Cong X., Wang Y., Fei R., Jiang D., et al. Expression of tumor-specific cancer/testis antigens in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 11 (2003) 145-148
27. Shang X.Y., Chen H.S., Zhang H.G., Pang X.W., Qiao H., Peng J.R., et al. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin Cancer Res 10 (2004) 6946-6955
28. Chen C.H., Chen G.J., Lee H.S., Huang G.T., Yang P.M., Tsai L.J., et al. Expressions of cancer-testis antigens in human hepatocellular carcinomas. Cancer Lett 164 (2001) 189-195
29. Chen Q., Jackson H., Parente P., Luke T., Rizkalla M., Tai T.Y., et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci USA 101 (2004) 9363-9368
30. Jäger E., Gnjatic S., Nagata Y., Stockert E., Jäger D., Karbach J., et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97 (2000) 12198-12203
31. Baumgaertner P., Rufer N., Devevre E., Derre L., Rimoldi D., Geldhof C., et al. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res 66 (2006) 1912-1916
32. Vonderheide R.H., Hahn W.C., Schultze J.L., and Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10 (1999) 673-679
33. Miura N., Horikawa I., Nishimoto A., Ohmura H., Ito H., Hirohashi S., et al. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet Cytogenet 93 (1997) 56-62
34. Miura N., Maeda Y., Kanbe T., Yazama H., Takeda Y., Sato R., et al. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res 11 (2005) 3205-3209
35. Mizukoshi E., Nakamoto Y., Marukawa Y., Arai K., Yamashita T., Tsuji H., et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 43 (2006) 1284-1294
36. Liu Y.K., Yang K.Z., Wu Y.D., Gang Y.Q., and Zhu D.N. Treatment of advanced primary hepatocellular carcinoma by 131-I-anti-AFP. Lancet 1 (1983) 531-532
37. Tsukazaki K., Hayman E.G., and Ruoslahti E. Effects of ricin A chain conjugates of monoclonal antibodies to human alpha-fetoprotein and placental alkaline phosphatase on antigen-producing tumor cells in culture. Cancer Res 45 (1985) 1834-1838
38. Hanke P., Rabe C., Serwe M., Bohm S., Pagenstecher C., Sauerbruch T., et al. Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand J Gastroenterol 37 (2002) 949-955
39. Zerbini A., Pilli M., Soliani P., Ziegler S., Pelosi G., Orlandini A., et al. Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. J Hepatol 40 (2004) 102-109
40. Komori H., Nakatsura T., Senju S., Yoshitake Y., Motomura Y., Ikuta Y., et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 12 (2006) 2689-2697
41. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2 (1996) 1096-1103
42. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
43. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4 (2004) 941-952
44. Hoffmann T.K., Muller-Berghaus J., Ferris R.L., Johnson J.T., Storkus W.J., and Whiteside T.L. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 8 (2002) 1787-1793
45. Della Bella S., Gennaro M., Vaccari M., Ferraris C., Nicola S., Riva A., et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 89 (2003) 1463-1472
46. Gabrilovich D.I., Corak J., Ciernik I.F., Kavanaugh D., and Carbone D.P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3 (1997) 483-490
47. Ishida T., Oyama T., Carbone D.P., and Gabrilovich D.I. Defective function of langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol 161 (1998) 4842-4851
48. Ormandy L.A., Farber A., Cantz T., Petrykowska S., Wedemeyer H., Horning M., et al. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol 12 (2006) 3275-3282
49. Gabrilovich D.I., Ishida T., Nadaf S., Ohm J.E., and Carbone D.P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5 (1999) 2963-2970
50. Gabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 (1998) 4150-4166
51. Ohm J.E., Shurin M.R., Esche C., Lotze M.T., Carbone D.P., and Gabrilovich D.I. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 163 (1999) 3260-3268
52. Menetrier-Caux C., Montmain G., Dieu M.C., Bain C., Favrot M.C., Caux C., et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92 (1998) 4778-4791
53. Ratta M., Fagnoni F., Curti A., Vescovini R., Sansoni P., Oliviero B., et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100 (2002) 230-237
54. Park S.J., Nakagawa T., Kitamura H., Atsumi T., Kamon H., Sawa S., et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 173 (2004) 3844-3854
55. Yang A.S., and Lattime E.C. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 63 (2003) 2150-2157
56. Beissert S., Hosoi J., Grabbe S., Asahina A., and Granstein R.D. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol 154 (1995) 1280-1286
57. Steinbrink K., Graulich E., Kubsch S., Knop J., and Enk A.H. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 99 (2002) 2468-2476
58. Um S.H., Mulhall C., Alisa A., Ives A.R., Karani J., Williams R., et al. Alpha-fetoprotein impairs APC function and induces their apoptosis. J Immunol 173 (2004) 1772-1778
59. Gershon R.K., and Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18 (1970) 723-737
60. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6 (2006) 295-307
61. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2 (2002) 389-400
62. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5 (2005) 263-274
63. Ormandy L.A., Hillemann T., Wedemeyer H., Manns M.P., Greten T.F., and Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65 (2005) 2457-2464
64. Unitt E., Rushbrook S.M., Marshall A., Davies S., Gibbs P., Morris L.S., et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41 (2005) 722-730
65. Yang X.H., Yamagiwa S., Ichida T., Matsuda Y., Sugahara S., Watanabe H., et al. Increase of CD4(+)CD25(+) regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol (2006)
66. Yamaguchi R., Yano H., Iemura A., Ogasawara S., Haramaki M., and Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28 (1998) 68-77
67. Beckebaum S., Zhang X., Chen X., Yu Z., Frilling A., Dworacki G., et al. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 10 (2004) 7260-7269
68. Giannelli G., Fransvea E., Marinosci F., Bergamini C., Colucci S., Schiraldi O., et al. Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 161 (2002) 183-193
69. Jonuleit H., Schmitt E., Schuler G., Knop J., and Enk A.H. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192 (2000) 1213-1222
70. Shimizu J., Yamazaki S., and Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163 (1999) 5211-5218
71. Shimizu K., Fields R.C., Giedlin M., and Mule J.J. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USAs 96 (1999) 2268-2273
72. Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34 (2004) 336-344
73. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (2005) 3623-3633
74. Murillo O., Arina A., Tirapu I., Alfaro C., Mazzolini G., Palencia B., et al. Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin Cancer Res 9 (2003) 5454-5464
75. Pang R., and Poon R.T. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett (2006)
76. Huether A., Hopfner M., Baradari V., Schuppan D., and Scherubl H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 70 (2005) 1568-1578
77. Grunwald V., Wilkens L., Gebel M., Wirth T., Greten T.F., Kubicka S., et al. A phase II open label study of cetuximab in unresectable hepatocellular carcinoma. J Clin Oncol 24 (2006) 630S
78. Melero I., Shuford W.W., Newby S.A., Aruffo A., Ledbetter J.A., Hellstrom K.E., et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3 (1997) 682-685
79. Wan Y.L., Zheng S.S., Zhao Z.C., Li M.W., Jia C.K., and Zhang H. Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity. World J Gastroenterol 10 (2004) 195-199
80. He L., Zhang G., He Y., Zhu H., Zhang H., and Feng Z. Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma. Anticancer Res 25 (2005) 3309-3313
81. Greten T.F., and Ott M. CD40 in hepatocellular carcinoma: relevant or not?. Eur J Gastroenterol Hepatol 15 (2003) 113-114
82. Holub M., Zakeri S.M., Lichtenberger C., Pammer J., Paolini P., Leifeld L., et al. Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol 15 (2003) 119-126
83. Grewal I.S., and Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16 (1998) 111-135
84. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., and Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 (1998) 480-483
85. Ryschich E., Marten A., Schmidt E., Linnebacher M., Wentzensen N., Eisold S., et al. Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer. Eur J Cancer (2006)
86. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T., Yamamoto J., et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356 (2000) 802-807
87. Une Y., Kawata A., and Uchino J. Adopted immunochemotherapy using IL-2 and spleen LAK cell-randomized study. Nippon Geka Gakkai Zasshi 92 (1991) 1330-1333
88. Kawata A., Une Y., Hosokawa M., Wakizaka Y., Namieno T., Uchino J., et al. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone. Am J Clin Oncol 18 (1995) 257-262
89. Shi M., Zhang B., Tang Z.R., Lei Z.Y., Wang H.F., Feng Y.Y., et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 10 (2004) 1146-1151
90. Gonzalez-Carmona M.A., Marten A., Hoffmann P., Schneider C., Sievers E., Schmidt-Wolf I.G., et al. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int 26 (2006) 369-379
91. Butterfield L.H., Ribas A., Dissette V.B., Lee Y., Yang J.Q., De la Rocha P., et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 12 (2006) 2817-2825
92. Zhang L., Zhang H., Liu W., Wang H., Jia J., Si X., et al. Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA. Cell Immunol 238 (2005) 61-66
93. Wang X.H., Qin Y., Hu M.H., and Xie Y. Dendritic cells pulsed with hsp70-peptide complexes derived from human hepatocellular carcinoma induce specific anti-tumor immune responses. World J Gastroenterol 11 (2005) 5614-5620
94. Kumagi T., Akbar S.M., Horiike N., Kurose K., Hirooka M., Hiraoka A., et al. Administration of dendritic cells in cancer nodules in hepatocellular carcinoma. Oncol Rep 14 (2005) 969-973
95. Chi K.H., Liu S.J., Li C.P., Kuo H.P., Wang Y.S., Chao Y., et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 28 (2005) 129-135
96. Palmer D.H., Hussain S.A., and Johnson P.J. Gene- and immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther 5 (2005) 507-523
97. Iwashita Y., Tahara K., Goto S., Sasaki A., Kai S., Seike M., et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 52 (2003) 155-161
98. Lee W.C., Wang H.C., Hung C.F., Huang P.F., Lia C.R., and Chen M.F. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 28 (2005) 496-504
99. Kuang M., Peng B.G., Lu M.D., Liang L.J., Huang J.F., He Q., et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 10 (2004) 1574-1579
100. Butterfield L.H., Ribas A., Meng W.S., Dissette V.B., Amarnani S., Vu H.T., et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 9 (2003) 5902-5908
101. Zerbini A., Pilli M., Penna A., Pelosi G., Schianchi C., Molinari A., et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 66 (2006) 1139-1146
102. Ali M.Y., Grimm C.F., Ritter M., Mohr L., Allgaier H.P., Weth R., et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatol 43 (2005) 817-822
103. Kumada T., Nakano S., Takeda I., Sugiyama K., Osada T., Kiriyama S., et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25 (1997) 87-92
104. Colombo M., and Donato M.F. Prevention of hepatocellular carcinoma. Semin Liver Dis 25 (2005) 155-161
105. Zhao L., Mou D.C., Leng X.S., Peng J.R., Wang W.X., Huang L., et al. Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol 10 (2004) 2034-2038
106. Mou D.C., Leng X.S., Peng J.R., Zhao L., Wang W.X., Wang Y., et al. [Expression of MAGE-B genes in hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi 26 (2004) 40-42
107. Luo G., Huang S., Xie X., Stockert E., Chen Y.T., Kubuschok B., et al. Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun 2 (2002) 11
108. Chen H., Cai S., Wang Y., Zhao H., Peng J., Pang X., et al. Expression of the MAGE-1 gene in human hepatocellular carcinomas. Chin Med J (Engl) 113 (2000) 1112-1118
109. Kobayashi Y., Higashi T., Nouso K., Nakatsukasa H., Ishizaki M., Kaneyoshi T., et al. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. J Hepatol 32 (2000) 612-617
110. Chen C.H., Huang G.T., Lee H.S., Yang P.M., Yan M.D., Chen D.S., et al. High frequency of expression of MAGE genes in human hepatocellular carcinoma. Liver 19 (1999) 110-114
111. Tahara K., Mori M., Sadanaga N., Sakamoto Y., Kitano S., and Makuuchi M. Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer 85 (1999) 1234-1240
112. Yamashita N., Ishibashi H., Hayashida K., Kudo J., Takenaka K., Itoh K., et al. High frequency of the MAGE-1 gene expression in hepatocellular carcinoma. Hepatology 24 (1996) 1437-1440
113. Kariyama K., Higashi T., Kobayashi Y., Nouso K., Nakatsukasa H., Yamano T., et al. Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma. Br J Cancer 81 (1999) 1080-1087
114. Wu L.Q., Lu Y., Wang X.F., Lv Z.H., Zhang B., and Yang J.Y. Expression of cancer-testis antigen (CTA) in tumor tissues and peripheral blood of Chinese patients with hepatocellular carcinoma. Life Sci (2006)
115. Zhang W.M., Xiao G., Zhang M., Guo A.L., Dong Y., and Wen J.M. Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma. Zhonghua Bing Li Xue Za Zhi 34 (2005) 202-205
116. Wang Y., Han K.J., Pang X.W., Vaughan H.A., Qu W., Dong X.Y., et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol 169 (2002) 1102-1109
117. Yin Y.H., Li Y.Y., Qiao H., Wang H.C., Yang X.A., Zhang H.G., et al. TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma. Br J Cancer 93 (2005) 458-463
118. Capurro M., Wanless I.R., Sherman M., Deboer G., Shi W., Miyoshi E., et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125 (2003) 89-97
119. Liu Y.C., Chen C.J., Wu H.S., Chan D.C., Yu J.C., Yang A.H., et al. Telomerase and c-myc expression in hepatocellular carcinomas. Eur J Surg Oncol 30 (2004) 384-390
120. Stenner-Liewen F., Luo G., Sahin U., Tureci O., Koslovski M., Kautz I., et al. Definition of tumor-associated antigens in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 9 (2000) 285-290
121. Uemura M., Nouso K., Kobayashi Y., Tanaka H., Nakamura S., Higashi T., et al. Identification of the antigens predominantly reacted with serum from patients with hepatocellular carcinoma. Cancer 97 (2003) 2474-2479
122. Yoshida T., Okazaki N., Yoshino M., Okhura H., and Shimada Y. Phase II trial of high dose recombinant gamma-interferon in advanced hepatocellular carcinoma. Eur J Cancer 26 (1990) 545-546
123. The Gastrointestinal Tumor Study Group. A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular. Cancer 1990;66:135-9.
124. Takayama T., Makuuchi M., Sekine T., Terui S., Shiraiwa H., Kosuge T., et al. Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report. Cancer 68 (1991) 2391-2396
125. Lai C.L., Lau J.Y., Wu P.C., Ngan H., Chung H.T., Mitchell S.J., et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 17 (1993) 389-394
126. Colleoni M., Buzzoni R., Bajetta E., Bochicchio A.M., Bartoli C., Audisio R., et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer 72 (1993) 3196-3201
127. Kardinal C.G., Moertel C.G., Wieand H.S., Schutt A.J., O'Connell M.J., Wright K., et al. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma. Cancer 71 (1993) 2187-2190
128. Aldeghi R., Lissoni P., Barni S., Ardizzoia A., Tancini G., Piperno A., et al. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer 30A (1994) 167-170
129. Lotz J.P., Grange J.D., Hannoun L., Boudghene F., Amiot X., Lamarque D., et al. Treatment of unresectable hepatocellular carcinoma with a combination of human recombinant alpha-2b interferon and doxorubicin: results of a pilot study. Eur J Cancer 30A (1994) 1319-1325
130. Feun L.G., Savaraj N., Hung S., Reddy R., Jeffers L., Benedetto P., et al. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma. Am J Clin Oncol 17 (1994) 393-395
131. Lygidakis N.J., Pothoulakis J., Konstantinidou A.E., and Spanos H. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res 15 (1995) 543-550
132. Lygidakis N.J., Kosmidis P., Ziras N., Parissis J., and Kyparidou E. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem. J Interferon Cytokine Res 15 (1995) 467-472
133. Kountouras J., Boura P., Karolides A., Zaharioudaki E., and Tsapas G. Recombinant a2 interferon (a-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC). Hepatogastroenterology 42 (1995) 31-36
134. Bokemeyer C., Kynast B., Harstrick A., Laage E., Schmoll E., von Wussow P., et al. No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 35 (1995) 334-338
135. Stuart K., Tessitore J., and Huberman M. 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma. Am J Clin Oncol 19 (1996) 136-139
136. Haruta I., Yamauchi K., Aruga A., Komatsu T., Takasaki K., Hayashi N., et al. Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy. J Immunother Emphasis Tumor Immunol 19 (1996) 218-223
137. Ji S.K., Park N.H., Choi H.M., Kim Y.W., Lee S.H., Lee K.H., et al. Combined cis-platinum and alpha interferon therapy of advanced hepatocellular carcinoma. Korean J Intern Med 11 (1996) 58-68
138. Wang Y., Chen H., Wu M., Bao J., Cong W., and Wang H. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes. Chin Med J (Engl) 110 (1997) 114-117
139. Stefanini G.F., Foschi F.G., Castelli E., Marsigli L., Biselli M., Mucci F., et al. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. Hepatogastroenterology 45 (1998) 209-215
140. Llovet J.M., Sala M., Castells L., Suarez Y., Vilana R., Bianchi L., et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31 (2000) 54-58
141. Ikeda K., Arase Y., Saitoh S., Kobayashi M., Suzuki Y., Suzuki F., et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32 (2000) 228-232
142. Kubo S., Nishiguchi S., Hirohashi K., Tanaka H., Shuto T., Yamazaki O., et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134 (2001) 963-967
143. Reinisch W., Holub M., Katz A., Herneth A., Lichtenberger C., Schoniger-Hekele M., et al. Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma. J Immunother 25 (2002) 489-499
144. Palmieri G., Montella L., Milo M., Fiore R., Biondi E., Bianco A.R., et al. Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma. Am J Clin Oncol 25 (2002) 224-226
145. Ladhams A., Schmidt C., Sing G., Butterworth L., Fielding G., Tesar P., et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 17 (2002) 889-896
146. Patt Y.Z., Hassan M.M., Lozano R.D., Brown T.D., Vauthey J.N., Curley S.A., et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 21 (2003) 421-427
147. Stift A., Friedl J., Dubsky P., Bachleitner-Hofmann T., Schueller G., Zontsich T., et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol 21 (2003) 135-142
148. Feun L.G., O'Brien C., Molina E., Rodriguez M., Jeffers L., Schiff E.R., et al. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial. J Cancer Res Clin Oncol 129 (2003) 17-20
149. Komorizono Y., Kohara K., Oketani M., Maeda M., Shibathou T., Shigenobu S., et al. Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study. Dig Dis Sci 48 (2003) 877-881
150. Sangro B., Mazzolini G., Ruiz J., Herraiz M., Quiroga J., Herrero I., et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22 (2004) 1389-1397
151. Chen S., Li B., Xie H., Xu L., Niu G., Fan K., et al. Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma. Cancer Biother Radiopharm 19 (2004) 589-600
152. Yin X.Y., Lu M.D., Liang L.J., Lai J.M., Li D.M., and Kuang M. Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma. World J Gastroenterol 11 (2005) 2526-2529
153. Golgher D., Jones E., Powrie F., Elliott T., and Gallimore A. Depletion of CD25+ regulatory cells uncover immune responses to shared murine tumor rejection antigens. Eur J Immunol 32 (2002) 3267-3275